Table 3.
Characteristics of Single (n=52) and the Re-Exacerbator Cohort (n=28)
| Demographics | Single Exacerbators (n = 52) | Re-Exacerbators (n = 28) |
|---|---|---|
| Age, ayears | 69 ± 8 | 68 ± 9 |
| Gender, Male (Female) | 27 (25) | 13 (15) |
| Duration of COPD, ayears | 10 ± 7 | 8 ± 6 |
| *FEV1, a(% predicted) | 48 ± 19 | 43 ± 15 |
| MRC Score, bn | 3.0, 1.0 | 3.0, 1.5 |
| Exacerbations in the previous 1 year, an | 4.0 ± 2.0 | 4.8 ± 2.8 |
| Exacerbations in the study, an | 1.0 | 2.2 ± 0.4 |
| Co-morbidities | ||
| None | 14 | 4 |
| Cardiovascular | 24 | 15 |
| Type 2 Diabetes Mellitus | 6 | 8 |
| Other | 6 | 12 |
| Total Co-morbidities an | 1.2 ± 1.0 | 1.5 ± 0.9 |
| COPD Medications | ||
| β2 Agonists, Short Acting, (Long Acting) | 52, (46) | 26, (26) |
| Anticholinergic, Short Acting, (Long Acting) | 4, (36) | 1, (24) |
| Inhaled Steroid | 46 | 27 |
| Oral Theophylline | 10 | 6 |
Notes: Data presented as aMean ± standard deviation and bMedian, interquartile range. *Statistically significant difference (p<0.001).
Abbreviations: COPD, chronic obstructive pulmonary disease; n, number; FEV1, forced expiratory volume in 1 second; BMI, body mass index; kg, kilogram; m, meter; MRC, medical research council; AECOPD, acute exacerbation of chronic obstructive pulmonary disease.